Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

Metric	Value
Current Market Cap	$98.08M
Last Price	$6.43
52-Week High	$17.44
52-Week Low	$6.01

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACET	$6.43	+0.00%	0.18M
3
4
5

Adicet Bio Inc. (ACET) Market Capitalization

Market Cap Data

Get Adicet Bio Inc. Data in Excel

More ACET Financial Data